Medidata, a global provider of cloud-based solutions and data analytics for clinical research, has agreed to acquire Mytrus, an eClinical technology company specializing in patient-centered electronic informed consent (eConsent) and virtual trials.
Medidata will integrate Enroll, Mytrus’ eConsent solution, into the Medidata Clinical Cloud as part of its ongoing commitment to modernize clinical trials for patients, sites and sponsors. With widespread support from international regulatory agencies, recent FDA guidance documents, industry groups like Transcelerate and large central IRBs, the clinical research and bio banking industries are rapidly adopting eConsent as a preferred alternative to paper. The addition of Enroll to Medidata’s cloud platform will allow Medidata to comprehensively address the industry’s conversion to this new technology.
Specific benefits include:
“The informed consent process is one of the most important parts of running both ethical and effective research projects. It's also the first step in giving patients a 21st Century experience, helping the critical elements of patient enrollment and retention in projects advancing healthcare," said Medidata’s President Glen de Vries. “Adding eConsent to the Medidata platform reinforces our commitment to improving patient engagement by delivering better tools, more data and higher quality insights for patients and researchers.”
“Patients are the cornerstone of clinical research and they have the right to simple and convenient access to study information,” stated Mytrus CEO, Anthony Costello. “Our goal at Mytrus has always been to build technology that enables patients to be more connected to research. Together with Medidata, we will be able to quickly advance this mission and extend the reach of our products to more patients, on more studies, in more countries.”
Mytrus’ Enroll will become part of Medidata Patient Cloud, a comprehensive and regulatory-compliant mHealth solution built to accelerate patient-centric clinical research. Patient Cloud’s current offerings include AppConnect, SensorLink and ePRO, which enable sponsors to collect subjective patient data through electronic clinical outcome assessments (eCOA) and patient-reported outcomes (ePRO) and objective data directly from patients using a variety of wearables and sensor technologies. The expanded Patient Cloud offering will now provide patients with a simplified, multimedia consent process, improving the patient experience from start to finish.
“eConsent is rapidly becoming a strategic capability within the clinical trial landscape. It makes trial participation easier and more intuitive for patients, and sets the foundation for more advanced analytics for sponsors,” said Marisa Co, vice president, Business Insights and Analytics for Bristol-Myers Squibb. “Mytrus is a seamless fit within the Medidata Clinical Cloud, particularly with Medidata's patient engagement solution and mHealth offerings. We look forward to integrating this new unified capability to bring a more efficient consent process, reinforcing our continued efforts to improve the patient experience.”
It is anticipated that Medidata’s acquisition of Mytrus will be completed in April 2017, subject to customary closing conditions.